risankizumab psoriatic arthritis
Selected indexed studies
- Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. (Ann Rheum Dis, 2022) [PMID:34911706]
- Risankizumab for the treatment of active psoriatic arthritis in adults. (Expert Rev Clin Immunol, 2023) [PMID:37772959]
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. (Ann Rheum Dis, 2024) [PMID:38503473]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. (2020) pubmed
- Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation. (2024) pubmed
- Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. (2024) pubmed
- Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial. (2022) pubmed
- Risankizumab for the treatment of active psoriatic arthritis in adults. (2023) pubmed
- Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial. (2022) pubmed
- Risankizumab in Adults with Psoriatic Arthritis. (2023) pubmed
- PMID:40493728 (2022) pubmed
- Effectiveness of risankizumab for the treatment of psoriatic arthritis: a multicenter, real-world study. (2024) pubmed
- Efficacy and Safety of Risankizumab in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (2024) pubmed